REGENXBIO Inc. (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $29.33, for a total transaction of $293,300.00. Following the completion of the transaction, the insider now owns 108,630 shares of the company’s stock, valued at $3,186,117.90. The sale was disclosed in a legal filing with the SEC, which is available at this link.

REGENXBIO Inc. (RGNX) traded down 3.91% during trading on Friday, reaching $28.25. 346,518 shares of the company were exchanged. REGENXBIO Inc. has a one year low of $13.61 and a one year high of $30.25. The company’s market capitalization is $872.76 million. The firm’s 50-day moving average is $27.39 and its 200 day moving average is $27.39.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.34. The firm had revenue of $6.56 million for the quarter. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. On average, analysts anticipate that REGENXBIO Inc. will post ($2.94) EPS for the current fiscal year.

WARNING: “REGENXBIO Inc. (RGNX) Insider Sells $293,300.00 in Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/22/regenxbio-inc-rgnx-insider-sells-293300-00-in-stock.html.

Several brokerages have recently commented on RGNX. Evercore ISI began coverage on shares of REGENXBIO in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price for the company. Bank of America Corporation upped their price objective on shares of REGENXBIO from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday. BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Chardan Capital upped their price objective on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Saturday, August 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $36.20.

A number of institutional investors have recently made changes to their positions in RGNX. Redmile Group LLC bought a new position in REGENXBIO in the 1st quarter worth about $24,494,000. State Street Corp boosted its stake in REGENXBIO by 178.1% in the 2nd quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock worth $17,399,000 after purchasing an additional 564,129 shares in the last quarter. GMT Capital Corp boosted its stake in REGENXBIO by 1,086.2% in the 2nd quarter. GMT Capital Corp now owns 609,700 shares of the biotechnology company’s stock worth $12,346,000 after purchasing an additional 558,300 shares in the last quarter. Citadel Advisors LLC boosted its stake in REGENXBIO by 625.1% in the 1st quarter. Citadel Advisors LLC now owns 559,887 shares of the biotechnology company’s stock worth $10,806,000 after purchasing an additional 482,667 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in REGENXBIO by 23.2% in the 1st quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock worth $18,942,000 after purchasing an additional 184,700 shares in the last quarter. Institutional investors own 73.23% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.